Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial

Journal of Clinical Oncology

Volumn 31, Issue 1, 2013, Pages 23-29

  Gourgou Bourgade, Sophie ^a   Bascoul Mollevi, Caroline ^a   Desseigne, Françoise ^b   Ychou, Marc ^a   Bouché, Olivier ^c   Guimbaud, Rosine ^d   Bécouarn, Yves ^e   Adenis, Antoine ^f   Raoul, Jean Luc ^g   Boige, Valérie ^h   Bérille, Jocelyne ⁱ   Conroy, Thierry ^j  

^a CENTRE VAL D AURELLE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c SERVICE DE DERMATOLOGIE   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

^e INSTITUT BERGONIÉ   (France)

^f CENTRE OSCAR LAMBRET   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ UNICANCER   (France)

^j UNIVERSITÉ DE LORRAINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; COGNITION; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; EMOTION; FATIGUE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; INSOMNIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PAIN; PANCREAS CANCER; PATIENT COMPLIANCE; PERITONEUM METASTASIS; PRIORITY JOURNAL; QUALITY OF LIFE; SOCIAL INTERACTION; TREATMENT DURATION;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL RATE;

EID: 84871723767     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.4869     Document Type: Article

References (21)

1. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
2. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
3. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
4. Conroy T, Mercier M, Bonneterre J, et al: French version of FACT-G: Validation and comparison with other cancer-specific instruments. Eur J Cancer 40:2243-2252, 2004
5. Fayers P, Aaronson N, Boral K, et al: EORTC QLQ-C30 Scoring Manual. Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001
6. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 16:297-334, 1951
7. Bonnetain F, Dahan L, Maillard E, et al: Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic cancer. Eur J Cancer 46:2753-2762, 2010
8. Quinten C, Coens C, Mauer M, et al: Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10:865-871, 2009
9. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996
10. Harrel F: Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. New York, NY, Springer, 2001
11. Kris MG, Benowitz SI, Adams S, et al: Clinical cancer advances 2010: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 28:5327-5347, 2010
12. Kim R: FOLFIRINOX: A new standard treatment for advanced pancreatic cancer? Lancet Oncol 12:8-9, 2011
13. Ko AH: FOLFIRINOX: A small step or a great leap forward? J Clin Oncol 29:3727-3729, 2011
14. Saif MW, Chabot J: Chemotherapy: Metastatic pancreatic cancer - Is FOLFIRINOX the new standard? Nat Rev Clin Oncol 8:452-453, 2011
15. Vaccaro V, Sperduti I, Milella M: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 365:768-769, 2011 (author reply 769)
16. Efficace F, Bottomley A, Coens C, et al: Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 42:42-49, 2006
17. Gotay CC, Kawamoto CT, Bottomley A, et al: The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355-1363, 2008
18. Montazeri A: Quality of life as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102, 2009
19. Lis CG, Gupta D, Grutsch JF: Patient satisfaction with quality of life as a predictor of survival in pancreatic cancer. Int J Gastrointest Cancer 37:35-44, 2006
20. Robinson DW Jr, Eisenberg DF, Cella D, et al: The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J Support Oncol 6:283-290, 2008
21. Bernhard J, Dietrich D, Glimelius B, et al: Estimating prognosis and palliation based on tumor marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer 103:1318-1324, 2010